Zymeworks Inc.
Anti-PD-1/LAG3 bispecific antibodies
Last updated:
Abstract:
Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments. Also provided here are methods and uses of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.
Status:
Grant
Type:
Utility
Filling date:
31 Jan 2019
Issue date:
27 Jul 2021